FindTrial
Sign In

Spexotras 0.05 mg/ml powder for oral solution

DRUG2 trials

Sponsors

Princess Maxima Center For Pediatric Oncology, Oslo University Hospital HF

Conditions

Acute Lymphoblastic LeukemiaCancerin Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Phase 1

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D
RecruitingCTIS2022-501869-41-00
Princess Maxima Center For Pediatric OncologyAcute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Start: 2023-11-14Target: 20Updated: 2025-08-04

Phase 2

Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.
RecruitingCTIS2024-513779-42-02
Oslo University Hospital HFCancer
Start: 2025-03-27Target: 100Updated: 2025-10-10

Related Papers

HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children
Blood2025-11-03